ATE239694T1 - Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung - Google Patents

Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung

Info

Publication number
ATE239694T1
ATE239694T1 AT96935424T AT96935424T ATE239694T1 AT E239694 T1 ATE239694 T1 AT E239694T1 AT 96935424 T AT96935424 T AT 96935424T AT 96935424 T AT96935424 T AT 96935424T AT E239694 T1 ATE239694 T1 AT E239694T1
Authority
AT
Austria
Prior art keywords
production
lower alkoxy
substituted
represents hydrogen
carboxy
Prior art date
Application number
AT96935424T
Other languages
English (en)
Inventor
Susumu Tsuchiya
Nobuyuki Yasuda
Toshifumi Matsumoto
Kozo Hiratsuka
Hiroyuki Iizuka
Atsusi Hukuzaki
Kouichi Matsunaga
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of ATE239694T1 publication Critical patent/ATE239694T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96935424T 1995-10-26 1996-10-24 Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung ATE239694T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27855495 1995-10-26
JP24962296 1996-09-20
PCT/JP1996/003097 WO1997015549A1 (en) 1995-10-26 1996-10-24 PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME

Publications (1)

Publication Number Publication Date
ATE239694T1 true ATE239694T1 (de) 2003-05-15

Family

ID=26539396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96935424T ATE239694T1 (de) 1995-10-26 1996-10-24 Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung

Country Status (12)

Country Link
US (1) US6069176A (de)
EP (1) EP0940387B1 (de)
JP (1) JP3926390B2 (de)
KR (1) KR100483635B1 (de)
AT (1) ATE239694T1 (de)
AU (1) AU715216B2 (de)
CZ (1) CZ126598A3 (de)
DE (1) DE69628051T2 (de)
ES (1) ES2193266T3 (de)
HU (1) HUP9802318A3 (de)
NO (1) NO981858L (de)
WO (1) WO1997015549A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263659A1 (en) * 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
WO1998024754A1 (en) * 1996-12-04 1998-06-11 Kureha Kagaku Kogyo Kabushiki Kaisha Cyclopentylamine derivatives, process for the preparation thereof, and bactericides
WO1999051564A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
EP0982026B1 (de) * 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern
ATE326219T1 (de) * 1998-08-18 2006-06-15 Hoffmann La Roche Verwendung von aryl-cyclohexylamine derivaten zur herstellung von nmda-rezeptorblockern
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
EP1258253A1 (de) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Neue heilmittel mit verwendung eines beta3-antagonisten
MXPA02009659A (es) 2000-04-26 2003-03-10 Warner Lambert Co Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda.
MXPA02010863A (es) * 2000-06-01 2003-03-27 Warner Lambert Co Derivados de ciclohexilamina como subtipo de antagonistas del receptor nmda selectivo.
ATE301642T1 (de) * 2000-06-06 2005-08-15 Warner Lambert Co Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
AU2003225277A1 (en) * 2002-05-02 2003-11-17 Robert Harris Lipid removal from the body
GB0217211D0 (en) 2002-07-24 2002-09-04 Syngenta Participations Ag Organic compounds
CA2503570C (en) 2002-11-07 2011-04-19 Yamanouchi Pharmaceutical Co., Ltd. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
SI1599468T1 (sl) * 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005042021A2 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
US20050250944A1 (en) * 2004-05-04 2005-11-10 Jian Chen Synthesis and uses of synephrine derivatives
AU2005293266B2 (en) * 2004-10-12 2011-09-29 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
JP4889501B2 (ja) * 2004-10-20 2012-03-07 田辺三菱製薬株式会社 フェニルエタノールアミン化合物の製造方法及びその中間体
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
JPWO2007083640A1 (ja) * 2006-01-18 2009-06-11 杏林製薬株式会社 頻尿及び尿失禁の予防又は治療剤
WO2008024787A1 (en) * 2006-08-23 2008-02-28 Medicinova, Inc. Method of treatment or prophylaxis of depression
KR100821567B1 (ko) 2006-11-01 2008-04-15 한국화학연구원 광학 활성 2-설포닐옥시-1-페닐에탄올 유도체의 제조방법
EP2066619A2 (de) * 2006-11-02 2009-06-10 Arete Therapeutics, INC. Lösliche epoxidhydrolasehemmer
US8217027B2 (en) * 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
MX2009012685A (es) * 2007-05-31 2009-12-14 Sepracor Inc Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
CA2706076A1 (en) * 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
EP2588445A1 (de) * 2010-06-30 2013-05-08 Leo Pharma A/S Neue polymorphe form einer calcimimetischen verbindung
US8946474B2 (en) * 2010-06-30 2015-02-03 Leo Pharma A/S Polymorphic form of a calcimimetic compound
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
PE20131341A1 (es) 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
JP6450660B2 (ja) * 2014-08-25 2019-01-09 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4940226B1 (de) * 1970-05-02 1974-10-31
US3803232A (en) * 1970-09-30 1974-04-09 Ciba Geigy Corp Arylcarboxamidines
JPS517617B2 (de) * 1972-08-25 1976-03-09
US4350685A (en) * 1981-02-06 1982-09-21 Smithkline Corporation Antiallergic imidodisulfamides
JPS62198639A (ja) * 1986-02-26 1987-09-02 Takasago Corp α−アリ−ルカルボニル誘導体の製造法
US4755505A (en) * 1987-08-18 1988-07-05 American Home Products Corporation 1-[2-(dialkylamino)alkyl]-4,5-dihydro-4-(aryl)-1-benzazocine-2,6(1H,3H)-diones as anti-arrhythmic agents
JPH0819032B2 (ja) * 1987-11-20 1996-02-28 三井東圧化学株式会社 ２−（４−ヒドロキシフェニル）−シクロヘキサノンの製造方法
FR2643076B1 (fr) * 1989-02-14 1991-06-21 Midy Spa Carboxyalkyl-ethers de la 2-amino-7-hydroxytetraline
DE4006937A1 (de) * 1990-03-06 1991-09-12 Basf Ag 4-(4-tert.-butylphenyl)cyclohexylamine und diese enthaltende fungizide
JP2971938B2 (ja) * 1990-11-01 1999-11-08 ダイセル化学工業株式会社 分離剤
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JP2932330B2 (ja) * 1991-10-28 1999-08-09 雪印乳業株式会社 含窒素化合物の水素化還元方法
DE4210569A1 (de) * 1992-03-31 1993-10-07 Hoechst Ag Verwendung von substituierten µ-Hydroxyethylaminen als fungizide Wirkstoffe

Also Published As

Publication number Publication date
AU715216B2 (en) 2000-01-20
NO981858D0 (no) 1998-04-24
HUP9802318A3 (en) 2001-04-28
NO981858L (no) 1998-06-24
WO1997015549A1 (en) 1997-05-01
KR100483635B1 (ko) 2005-12-21
AU7335896A (en) 1997-05-15
EP0940387A1 (de) 1999-09-08
EP0940387B1 (de) 2003-05-07
US6069176A (en) 2000-05-30
KR19990067089A (ko) 1999-08-16
EP0940387A4 (de) 2000-07-05
ES2193266T3 (es) 2003-11-01
HUP9802318A2 (hu) 1999-08-30
JP3926390B2 (ja) 2007-06-06
DE69628051T2 (de) 2004-02-26
CZ126598A3 (cs) 1998-09-16
DE69628051D1 (de) 2003-06-12

Similar Documents

Publication Publication Date Title
DE69628051D1 (de) Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
EP0846693A4 (de) N-benzyldioxothiazolidylbenzamid-derivate und verfahren zu ihrer herstellung
ATE219071T1 (de) Tricyclische verbindungen mit bindungsaffinität für melatoninrezeptoren, deren herstellung und verwendung
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
DE60330015D1 (de) Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten
DE50307267D1 (de) Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
UA35564C2 (uk) Поліциклічні аміновмісні сполуки, що є антагоністами рецепторів нейрокінінів, їх фармацевтично прийнятні енантіомери, солі, n-оксиди і продукти кватернізації, спосіб їх отримання, проміжні сполуки і фармацевтична композиція
UA86760C2 (ru) Замещенные n-арилгетероциклы, способ их получения и их применение в качестве лекарственных средств
ATE229527T1 (de) Pyrazolopyridylpyrazinon-derivate und ein verfahren zu ihrer herstellung
ATE381559T1 (de) Adamantan- und azabicyclooctan- und - nonanderivate, verfahren zu deren herstellung und deren verwendung als dpp-iv-inhibitoren
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
EP1123918A4 (de) Aromatische aminderivate, verfahren zu ihrer herstellung und mittel, die diese enthalten
ATE158790T1 (de) Substituierte 1,2,3,4- tetrahydrocyclopent(b>indole, 1,2,3,3a,4,8a- hexahydrocyclopent(b>indole und verwandte verbindungen, zwischenprodukte und ein verfahren zur herstellung derselben und ihre verwendung als medikamente
ATE267799T1 (de) Ein verfahren zur herstellung von (2s,2'r,3'r)-2- (2,3-dicarboxycyclopropyl)-glycin
DE50310200D1 (de) Verfahren zur herstellung von aminoalkoxybenzylaminen und aminoalkoxybenzonitrilen als zwischenprodukte
DE59709792D1 (de) Ringannelierte dihydropyrane, verfahren zur herstellung sowie deren verwendung
IT1303123B1 (it) Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed
ATE234828T1 (de) Hydronaphtho(2,3-c)furan-derivate und verfahren zu ihrer herstellung
EP1496059A4 (de) Kondensierte bicyclische pyrimidinderivate
ATE270287T1 (de) 2,3-dihydro-1h-isoindolderivate, verfahren zu ihrer herstellung und ihre verwendung als hemmer der serotoninwiederaufnahme
DE69928890D1 (de) 2-Amino-Pyridin Zwischenprodukte für beta3-Adrenergischer Rezeptor-Agoniste
ATE300534T1 (de) Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen
BRPI0417147A (pt) processo para preparação de derivados de (3-oxo-2,3-dihidro-1h-isoindol-1-il)-acetilguanidinas
ATE311382T1 (de) Verfahren zur herstellung von 2-carbamoyl- pyridinen
PT786459E (pt) Processo para a preparacao de um enantiomero de alcool heterobiciclico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties